Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Importance: Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to anthracycline use. Objective: To test whether atorvastatin is associated with a reduction in the proportion of patients with lymphoma receiving anthracyclines who develop cardiac dysfunction. Design, Setting, and Participants: Double-blind randomized clinical trial conducted at 9 academic medical centers in the US and Canada among 300 patients with lymphoma who were scheduled to receive anthracycline-based chemotherapy. Enrollment occurred between January 25, 2017, and September 10, 2021, with final follow-up on October 10, 2022. Interventions: Participants were randomized to receive atorvastatin, 40 mg/d (n = 150), or placebo (n = 150) for 12 months. Main Outcomes and Measures: The primary outcome was the proportion of participants with an absolute decline in left ventricular ejection fraction (LVEF) of ≥10% from prior to chemotherapy to a final value of <55% over 12 months. A secondary outcome was the proportion of participants with an absolute decline in LVEF of ≥5% from prior to chemotherapy to a final value of <55% over 12 months. Results: Of the 300 participants randomized (mean age, 50 [SD, 17] years; 142 women [47%]), 286 (95%) completed the trial. Among the entire cohort, the baseline mean LVEF was 63% (SD, 4.6%) and the follow-up LVEF was 58% (SD, 5.7%). Study drug adherence was noted in 91% of participants. At 12-month follow-up, 46 (15%) had a decline in LVEF of 10% or greater from prior to chemotherapy to a final value of less than 55%. The incidence of the primary end point was 9% (13/150) in the atorvastatin group and 22% (33/150) in the placebo group (P = .002). The odds of a 10% or greater decline in LVEF to a final value of less than 55% after anthracycline treatment was almost 3 times greater for participants randomized to placebo compared with those randomized to atorvastatin (odds ratio, 2.9; 95% CI, 1.4-6.4). Compared with placebo, atorvastatin also reduced the incidence of the secondary end point (13% vs 29%; P = .001). There were 13 adjudicated heart failure events (4%) over 24 months of follow-up. There was no difference in the rates of incident heart failure between study groups (3% with atorvastatin, 6% with placebo; P = .26). The number of serious related adverse events was low and similar between groups. Conclusions and Relevance: Among patients with lymphoma treated with anthracycline-based chemotherapy, atorvastatin reduced the incidence of cardiac dysfunction. This finding may support the use of atorvastatin in patients with lymphoma at high risk of cardiac dysfunction due to anthracycline use. Trial Registration: ClinicalTrials.gov Identifier: NCT02943590
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Cited by
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75
“52 In addition, many shared risk factors exist for cancer and HF that support prioritizing preventive measures for shared benefits in cancer and HF outcomes, which has been the focus of 2 previous AHA scientific statements.”
Oikonomou, E. K., Sangha, V., Dhingra, L. S., Aminorroaya, A., Coppi, A., Krumholz, H. M., Baldassarre, L. A., & Khera, R. (2025) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011504 · Cited by 60
Metadata
- Authors
- Neilan, T. G., Quinaglia, T., Onoue, T., Mahmood, S. S., Drobni, Z. D., Gilman, H. K., Smith, A., Heemelaar, J. C., Brahmbhatt, P., Ho, J. S., Sama, S., Svoboda, J., Neuberg, D. S., Abramson, J. S., Hochberg, E. P., Barnes, J. A., Armand, P., Jacobsen, E. D., Jacobson, C. A., Kim, A. I., Soumerai, J. D., Han, Y., Friedman, R. S., Lacasce, A. S., Ky, B., Landsburg, D., Nasta, S., Kwong, R. Y., Jerosch-Herold, M., Redd, R. A., Hua, L., Januzzi, J. L., Asnani, A., Mousavi, N., & Scherrer-Crosbie, M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-08-08
- Volume
- 330
- Issue
- 6
- Pages
- 528
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4385658384
- Cited by
- 215
- References
- 2
- FWCI
- 37.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2023.11887
- The paper
- Neilan, T. G., Quinaglia, T., Onoue, T., Mahmood, S. S., Drobni, Z. D., Gilman, H. K., Smith, A., Heemelaar, J. C., Brahmbhatt, P., Ho, J. S., Sama, S., Svoboda, J., Neuberg, D. S., Abramson, J. S., Hochberg, E. P., Barnes, J. A., Armand, P., Jacobsen, E. D., Jacobson, C. A., . . . Scherrer-Crosbie, M. (2023). Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.11887
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.